In a first, Otsuka's Voyxact stabilizes IgAN kidney loss in ph.3
Otsuka's Voyxact stabilized kidney function decline in IgAN patients in a Phase 3 trial, a first for the indication.
Otsuka Holdings
Otsuka is a small molecule pharma company covered in the openbionews harvest.
Company Info
Recent News
Otsuka’s ADHD approval opens up new drug class with $615M opportunity
Otsuka’s ADHD approval opens up new drug class with $615M opportunity.
Leadership Team
Careers & Job Openings